Clinical Trials Logo

Traveler's Diarrhea clinical trials

View clinical trials related to Traveler's Diarrhea.

Filter by:
  • None
  • Page 1

NCT ID: NCT04027894 Not yet recruiting - Traveler's Diarrhea Clinical Trials

Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years

Start date: January 2024
Phase: Phase 2
Study type: Interventional

This will be a double blind comparative study, performed in pediatric subjects (Age 12-17) traveling to developing regions with a known high incidence of traveler's diarrhea. The subjects will be suffering from acute diarrhea for at least 12 hours, without symptoms of systemic infection.

NCT ID: NCT04026984 Not yet recruiting - Traveler's Diarrhea Clinical Trials

Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years

Start date: June 2024
Phase: Phase 2
Study type: Interventional

This will be a double-blind comparative study, performed in pediatric subjects (Age 6-11) traveling to developing regions with a known high incidence of traveler's diarrhea. The subjects will be suffering from acute diarrhea for at least 12 hours, without symptoms of systemic infection.

NCT ID: NCT03866291 Completed - Clinical trials for Antibiotic Resistant Infection

ESBL in Patients Returning to Sweden With Traveller's Diarrhoea

Start date: February 1, 2017
Phase:
Study type: Observational

Patients with traveller's diarrhoea frequently harbour Extended Spectrum Betalactamase (ESBL)-producing Enterobacteriaceae (EPE) returning from EPE-endemic areas. This study investigates to what extent travellers returning to Sweden with traveller's diarrhoea carry ESBL in their stool. The isolates are examined further according to species, phenotype, antibiogram and whole genome sequencing.

NCT ID: NCT03301103 Completed - Traveler's Diarrhea Clinical Trials

PTM202 and Modulation of Host Resistance to Diarrheagenic E. Coli

APA12/PANTER
Start date: December 7, 2017
Phase: N/A
Study type: Interventional

The APA12/PANTER study is a parallel 3-weeks intervention study. Subjects will be randomly assigned to one of two treatment groups; placebo or PTM202 (n=36 per group). After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli at study day 14. At various time points before and after diarrheagenic E. coli challenge an online diary will be kept to record information on stool consistency, frequency and severity of symptoms and stool samples will be collected to determine total fecal wet weight and percentage of fecal wet weight.

NCT ID: NCT02736539 Withdrawn - Traveler's Diarrhea Clinical Trials

Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea

Start date: April 15, 2017
Phase: Phase 3
Study type: Interventional

This study is designed as a randomized double-blinded treatment trial among travelers' to geographical areas with moderate-severe rates of traveler's diarrhea. Travelers will be randomized to receive CBS 2004 or masked placebo to be taken daily while traveling. The test article or placebo will be taken starting 7 days prior to travel.

NCT ID: NCT01208922 Completed - Traveler's Diarrhea Clinical Trials

Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea

ERASE
Start date: November 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to prove the non-inferiority of Rifamycin SV-MMX® versus Ciprofloxacin for the treatment of adults with traveller's diarrhoea.

NCT ID: NCT01142089 Completed - Traveler's Diarrhea Clinical Trials

Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)

Start date: May 27, 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether Rifamycin SV MMX is a safe and effective treatment for Traveler's Diarrhea.

NCT ID: NCT01040325 Completed - Traveler's Diarrhea Clinical Trials

Traveler's Diarrhea (TD) Vaccine Asia Efficacy Study

Start date: December 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of the TD Vaccine System to prevent moderate to severe enterotoxin E.coli (ETEC) disease in travelers to India.

NCT ID: NCT00672035 Completed - Traveler's Diarrhea Clinical Trials

Prevention, Randomized, Double-Blinded, Placebo-Controlled, Parallel Assignment, Safety/Efficacy Study

Start date: October 2006
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the body's immune response to the LT patch at different doses. The secondary purpose of this study is to evaluate the safety of the LT patches at different doses and the safety of the skin preparation system. Another secondary purpose is to compare the safety and the body's immune response to LT patches placed on the upper arm versus the lower back.